Daniel O’Day is getting about $30 million in cash and stock to save the stagnant Gilead Sciences (GILD). On Thursday, investors get their first chance to decide whether he’s worth the money.

O’Day, who started as Gilead CEO in March, will host his first quarterly earnings call after the market closes, giving the Roche (RHHBY) veteran a chance to explain his vision for the company, weigh in on some recent setbacks, and get some practice answering the question he’ll face every three months from now on: What are you going to buy?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy